Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IDEAYA Biosciences (IDYA) Shares Outstanding (Weighted Average): 2019-2025

Historic Shares Outstanding (Weighted Average) for IDEAYA Biosciences (IDYA) over the last 7 years, with Sep 2025 value amounting to $87.6 million.

  • IDEAYA Biosciences' Shares Outstanding (Weighted Average) rose 3.74% to $87.6 million in Q3 2025 from the same period last year, while for Jun 2025 it was $87.6 million, marking a year-over-year increase of 15.72%. This contributed to the annual value of $86.4 million for FY2024, which is 34.09% up from last year.
  • Per IDEAYA Biosciences' latest filing, its Shares Outstanding (Weighted Average) stood at $87.6 million for Q3 2025, which was up 0.07% from $87.6 million recorded in Q2 2025.
  • Over the past 5 years, IDEAYA Biosciences' Shares Outstanding (Weighted Average) peaked at $87.6 million during Q3 2025, and registered a low of $32.3 million during Q1 2021.
  • Moreover, its 3-year median value for Shares Outstanding (Weighted Average) was $75.7 million (2024), whereas its average is $73.8 million.
  • Data for IDEAYA Biosciences' Shares Outstanding (Weighted Average) shows a peak YoY skyrocketed of 61.31% (in 2021) over the last 5 years.
  • IDEAYA Biosciences' Shares Outstanding (Weighted Average) (Quarterly) stood at $38.5 million in 2021, then increased by 24.98% to $48.1 million in 2022, then soared by 33.97% to $64.5 million in 2023, then skyrocketed by 34.09% to $86.4 million in 2024, then rose by 3.74% to $87.6 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $87.6 million for Q3 2025, versus $87.6 million for Q2 2025 and $87.5 million for Q1 2025.